CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.
February 7th 2020
The novel drug pairing of Venclexta and Gazyva, used for a fixed 12 months, is cost-effective compared with regimens that must be taken until disease progresses, a study finds.
January 17th 2020
With many targeted treatment options for patients with CLL to use upfront, the question arises as to which one is best for the individual.
January 16th 2020
A brief, multimodal psychosocial intervention for caregivers of patients undergoing hematopoietic stem cell transplantation could improve their quality of life, caregiving burden and anxiety and depression symptoms.
January 16th 2020
In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with the associate director of the Information Resource Center at the Leukemia and Lymphoma Society on support groups and other recourses available for those affected by blood cancer.
January 5th 2020
Researchers are exploring ways to limit the duration of treatment in chronic lymphocytic leukemia in order to reduce costs.
January 4th 2020
Those with follicular lymphoma and chronic lymphocytic leukemia who were treated with Zydelig in the clinical setting experienced less favorable outcomes, compared with those treated in a clinical trial.
December 30th 2019
As 2019 comes to a close, take a read through CURE®’s top stories of the year.
December 27th 2019
Take a look back at the top 10 podcasts of 2019 – and be sure to subscribe so you don’t miss an episode in 2020.
December 11th 2019
When one woman experienced symptoms of chronic lymphocytic leukemia, people blamed her nerves and told her to rest. Instead, she listened to her body.
December 10th 2019
Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.
November 28th 2019
The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.
November 21st 2019
In partnership with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the Food and Drug Administration (FDA) has granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
September 17th 2019
In what was once an incurable cancer — chronic lymphocytic leukemia — scientists are seeing remissions that could last for decades.
July 24th 2019
With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.
July 23rd 2019
The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.
June 18th 2019
Patients with chronic lymphocytic leukemia should learn about the latest advancements, says one expert.
June 6th 2019
The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.
May 31st 2019
Patients with chronic lymphocytic leukemia have newer options that include targeted therapy combinations and CAR-T cell therapy.